Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.69 |
| ▸ | RAF1 | P04049 | 2/20 | 0.62 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.62 |
| ▸ | FLT1 | P17948 | 3/20 | 0.49 |
| ▸ | FLT4 | P35916 | 3/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548774 | 0.86 | KDR (0.69) | KDRFLT1RET | |
| SCHEMBL4548801 | 0.84 | KDR (0.80) | KDRRAF1FLT1FLT4RET | |
| SCHEMBL4548796 | 0.82 | KDR (0.84) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL4556267 | 0.82 | KDR (1.00) | KDRRAF1FLT1FLT4TNNI3K | |
| SCHEMBL4548793 | 0.81 | KDR (0.84) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2748774 | 0.81 | KDR (0.68) | KDRRAF1BRAF | |
| SCHEMBL4548934 | 0.80 | KDR (0.68) | KDRRAF1RETBRAF | |
| SCHEMBL4548798 | 0.80 | KDR (0.83) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2747767 | 0.80 | KDR (0.77) | KDRRAF1FLT1FLT4RET | |
| SCHEMBL2434197 | 0.80 | KDR (0.70) | KDRRAF1FLT1FLT4TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885RAF1 1183/4885MAPK3 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.